Proactive.
Comprehensive.
Engaging.

Advancing the Treatment of Heart Failure. Together.

Insights to Transform Heart Failure Care

Empowering proactive heart failure management in the home

Successful heart failure (HF) management requires a combination of lifestyle changes and frequent medical therapy adjustments. With the FDA-approved Cordella PA Sensor and HF System, we make it easier for patients with NYHA class III heart failure, caregivers, and clinicians.

Proactive

PA Pressure Data

Guides HF management that may reduce congestion & improve outcomes1

Comprehensive

Vital Sign Data

Enables remote HF medication optimization1

Engaging

Heart Data Visibility

Encourages patient self-awareness & sustainable lifestyle decisions

Patient-First Focus

Delivers an accurate health status with daily data* collected from patient-friendly tools.

Encourages healthy lifestyle choices with patient visibility to health trends.

* PA pressure, Blood Pressure, Weight, Heart Rate, Blood Oxygen and Customizable Health Questions

Patient-First Focus

Delivers an accurate health status with daily data* collected from patient-friendly tools.

Encourages healthy lifestyle choices with patient visibility to health trends.

* PA pressure, Blood Pressure, Weight, Heart Rate, Blood Oxygen and Customizable Health Questions

Clinician-Directed Proactive Care

Enables new treatment standards with comprehensive, trended 
health data, including PA pressure.

Scalable workflow that aligns 
with care delivery and supports reimbursement.

Clinician-Directed Proactive Care

Enables new treatment standards with comprehensive, trended 
health data, including PA pressure.

Scalable workflow that aligns 
with care delivery and supports reimbursement.

Strengthened Partnership

Creates a connection to support meaningful improvements in patient health.

Strengthened Partnership

Creates a connection to support meaningful improvements in patient health.

Watch how Cordella helps patients embrace life again

Meet Tom

Meet David

THE EVIDENCE IS IN FOR NYHA CLASS III PATIENTS

Cordella is clinically proven to enable better heart failure management.2

Markedly low 12-month HF Hospitalization /
all-cause mortality rate (0.36)

Significant improvement in key quality of life metrics and functional capacity (KCCQ, 6-minute walk test, and NT-proBNP)*

Reduction in HF hospitalization rate before and after Cordella use at
12 months

*KCCQ (+5.7 points, p<0.0001), 6-minute walk text (+35 m, p=0.0004), NT-proBNP (-268 pg/mL, p=0.006)

DSRC: Device or System-Related Complications; KCCQ: Kansas City Cardiomyopathy Questionnaire

Read 6-month Results Intended Use

Cordella is now FDA Approved

for patients with NYHA class III Heart Failure

Heart failure (HF) is a debilitating, progressive disease that impacts everyday life.

  • 1 in 4 people will develop HF during their lifetime3
  • Climbing HF-related mortality rates4
  • After 65 the risk of HF increases dramatically5
  • Only 9.1% of HFrEF patients achieve optimal guideline-directed medical therapy (GDMT)6,7

It’s time to lead a more full and active life.

Learn about Cordella.

For Patients For Clinicians

of Cordella patients believe PA pressure monitoring & care has a positive health impact8

“[Cordella] is an amazing device. It’s a tool that everyone should have access to. It is the future of medicine in our minds.”

–Anita, Caregiver of a Cordella patient

What's New

Implantable PA sensor for heart failure linked to positive 1-year outcomes

Edwards Lifesciences agrees to acquire JenaValve, Endotronix for $1.2B

FDA Approves Cordella Remote PA Pressure Monitoring System for HF
See more +

References

  1. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. doi: 10.1161/CIR.0000000000001063.
  2. Klein L et al. Seated Pulmonary Artery Pressure Management in Patients with Heart Failure: 12-Month Outcomes in the PROACTIVE-HF Trial. Accepted in JACC-HF.
  3. Bozkurt B et al.  J Card Fail. 2023 Oct;29(10):1412-1451.
  4. Sayed A et al. JAMA Cardiol. 2024 Jun 1;9(6):585-589.
  5. HF Facts & Information. Heart Failure Society of America. https://hfsa.org/patient-hub/heart-failure-facts-information. Last accessed Oct 25, 2023.
  6. Mentias A et al. JACC Heart Fail. 2023 Oct 26:S2213-1779(23).
  7. Optimal triple GDMT was defined as ≥50% of the target daily dose of beta-blockers, ≥50% of the target daily dose of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker or any dose of sacubitril/valsartan, and any dose of mineralocorticoid receptor antagonist.
  8. Guichard JL et al. Presented at THT 2023.
Important Risk Information